Seaport Therapeutics and Hemab Therapeutics pushed forward with large, upsized IPOs, adding more capital to biotech as the public-market window stays open. Seaport joined Nasdaq with gross proceeds around $254.9 million, while Hemab priced an upsized offering for $301.5 million in gross proceeds. The listings deepen the set of newly public CNS and coagulation-focused companies and provide funding for later-stage clinical trial execution. They also suggest investor appetite for platform and differentiated modalities remains intact as long as early clinical signals and commercialization narratives are credible. For the sector, the two IPOs arrive alongside other equity-market activity referenced in broader IPO coverage, reinforcing that 2026 fundraising remains a key driver for development timelines.